On December 3, 2024, CVS Health announced the pricing of $3 billion in junior subordinated notes. The offering includes $2.25 billion of 7.000% Series A Notes due 2055 and $750 million of 6.750% Series B Notes due 2054. The settlement date is set for December 10, 2024.Interest on the Series A Notes will be paid semi-annually starting March 10, 2025, and on the Series B Notes starting June 10, 2025. Both series have optional deferral of interest for up to 10 years and are subject to redemption under specific conditions.The notes are rated Baa3 by Moody's and BB+ by S&P. Joint book-running managers include Barclays, Citigroup, Goldman Sachs, and others. The offering is part of a registration statement filed with the SEC.

On December 3, 2024, CVS Health announced the pricing of $3 billion in junior subordinated notes. The offering includes $2.25 billion of 7.000% Series A Notes due 2055 and $750 million of 6.750% Series B Notes due 2054. The settlement date is set for December 10, 2024.Interest on the Series A Notes will be paid semi-annually starting March 10, 2025, and on the Series B Notes starting June 10, 2025. Both series have optional deferral of interest for up to 10 years and are subject to redemption under specific conditions.The notes are rated Baa3 by Moody's and BB+ by S&P. Joint book-running managers include Barclays, Citigroup, Goldman Sachs, and others. The offering is part of a registration statement filed with the SEC.